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Abstract 
Heart failure (HF) with mid-range ejection fraction (HFmrEF)
has been conceptualized by the European Society of Cardiology
guidelines with the aim of stimulating research to fill a gap in
knowledge: whether such a condition exists as a distinct patho-
physiological and clinical entity, or it is just a residual category of
ejection fraction indeed is still a matter of debate. Current evi-
dence suggests that HFmrEF represents up to one fifth of patients
with HF, who may ultimately result in an intermediate clinical
phenotype, as for age and gender, with an intermediate prevalence
of comorbidities. Nevertheless, a strong connection exists with HF
with reduced ejection fraction, since ischemic aetiology is com-
mon in both categories, conveying relevant implications for prog-
nosis and therapeutic response. Little is known about its patho-
physiology: mild systolic impairment may be not enough and
advocating diastolic dysfunction may be an oversimplification. An
increasing amount of data is clarifying how many of HFmrEF
patients are the results of deteriorating or recovering hearts, thus
underscoring that aetiology may be, more than EF, the key to
understand this new category. Sparse evidence points toward a
potential benefit of common HF therapies in those patients, but
further research is still needed. 
Introduction
Heart failure (HF) has been historically categorized by left
ventricular ejection fraction (LVEF) values due to prognostic and
therapeutic implications, since most available interventions have
been able to reduce morbidity and mortality in those with LVEF
<35-40%. Beside this well-known group of patients with severe
systolic dysfunction, another category has gained scientific inter-
est: patients with HF symptoms, whose LVEF is preserved (i.e.,
>50%), but with evidence of cardiac abnormalities. Heart failure
with preserved LVEF (HFpEF) is currently topic of deep research,
and although an abnormal diastolic pattern has been advocated as
a major pathophysiological mechanism, whether it should be
looked as single disease or as multiple diseases with a common
underlying physiology, is still debated [1]. Between the two, a gap
has been left: patients whose EF is not severely impaired (or, at
least, not below the cut-off commonly used in most HF interven-
tion trials), but neither completely normal, thus not fulfilling the
criteria for HFpEF. 
This entity, already identified as a grey area of mild systolic
dysfunction in the 2012 European Society of Cardiology (ESC)
guidelines [2], later has been classified within the HF with pre-
served EF group by the 2013 ACCF/AHA guidelines [3]. Current
ESC guidelines define HF with mid-range EF (HFmrEF) as the
combination of signs and symptoms of HF with LVEF 40-49%
and markers of abnormal cardiac function or morphology: namely,
increased levels of natriuretic peptides and at least one between
left atrial enlargement and/or left ventricular hypertrophy, or left
ventricle diastolic dysfunction [4]. Stuck in the middle, HFmrEF
has eventually gained a formal recognition, but there are still large
gaps in understanding its epidemiology, aetiology, clinical pheno-
type, prognosis and potential treatments.
In this brief narrative review, we will focus on what is current-
ly known about HFmrEF, focusing on controversies and promis-
ing fields of research. 
Epidemiology and clinical profile
A recent population-based analysis of the Swedish Heart
Failure Registry [5] found that HFmrEF accounts for up to one-
fifth (21%) of HF patients. When comparing clinical profiles
across different EF ranges, HFmrEF proved to be a middle-earth
as for age, female gender, comorbidities (hypertension, atrial fib-
rillation, lung disease), with all these features being more preva-
lent than in HFrEF and quite close to that found in HFpEF, with
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the notable exception of diabetes, which was significantly more
prevalent in HFpEF. Where HFmrEF appeared to resemble HFrEF
was in prevalence of ischemic heart disease (IHD), which also por-
tended for both conditions a higher 1- and 3-year risk of death;
moreover, previous myocardial infarction and revascularisation
were more common in HFrEF and HFmrEF than in HFpEF [6].
Such a peculiarity is consistent with previous reports, suggesting
that IHD may be an aetiological link between HFrEF and HFmrEF.
A similar picture of HFmrEF derived from another wide popula-
tion-based registry from Japan [7], where HFmrEF resulted more
closely similar to HFpEF; prevalence was 17%, confirming that a
significant proportion of symptomatic, real world, HF patients falls
into the mid category. Bhambhani et al. [8], in their work on inci-
dent HF in a pooled population from four community-based longi-
tudinal cohorts, found an incidence of 6.7 cases per 10.000 person-
years for HFmrEF, compared to 26.9 and 34.9 cases for HFpEF
and HFrEF respectively. Differences in the prevalence and inci-
dence of HF categories may still depend on variable modalities of
enrolment and settings of patient management: HFpEF incidence
was higher in a community-based studies, and a bimodal distribu-
tion was more typical in hospital settings, compared to the uni-
modal distribution usually found across different ranges of EF in
outpatient studies.
Outcomes
In the Swedish Heart Failure [5] registry, all-cause mortality
was similar in HFmrEF and HFpEF after adjustment for age and
other confounders, and overall slightly less than in HFrEF, up to 3
years follow-up. Tsuji and colleagues [7] explored multiple prog-
nostic outcomes and found that incidence of HF hospitalization
was intermediate between HFpEF and HFrEF and all-cause and
cardiovascular mortality was closer to HFpEF, while no significant
differences were seen for non-cardiovascular mortality, acute
myocardial infarction or stroke among the three groups. They also
found that prognostic factors identified for HFmrEF (age>75
years, increased BNP, diuretics use, stroke and cancer) were shared
by HFpEF and HFrEF (with the notable exception of cancer and
diuretics use, the latter being shared only with HFrEF). Bhambhani
et al. [8] reported that all-cause mortality of HFmrEF was worse
than that of HFpEF (50 vs 39 events per 1000 person-years) but
comparable to that of HFrEF. The ESC Heart Failure Long-Term
Registry [9] showed that all-cause, one-year mortality was 8.8%
for HFrEF, 7.6% for HFmrEF and 6.4% in HFpEF (with a signifi-
cant difference only between HFpEF and HFrEF). As a whole,
available studies report slightly different prognostic profiles for
HFmrEF, with a trend suggesting a truly intermediate mid-term but
a better long-term prognosis, closer to that of HFpEF. 
Aetiology and pathophysiology
As reported, prevalence of IHD appears to be higher in
HFmrEF than in HFpEF. Such a finding is one of the most striking
and consistent across different observations. After adjusting for
possible confounders, Authors from the Swedish Registry [6] con-
firmed the meaningful asymmetric distribution of IHD among dif-
ferent EF ranges - namely 60% for HFrEF, 61% for HFmrEF and
52% for HFpEF (RR preserved vs midrange: 0.91). Tsuji et al. [7]
and Chioncel et al. [9] also reported about other aetiologies. When
compared to HFpEF, HFmrEF had an intermediate prevalence of
Hypertensive Heart Disease (HHD) in both studies (14.3% v.
24.5%, and 9.6% vs 18.1% respectively), but was more commonly
related to Dilated Cardiomiopathy (DCM) (20.3% vs 6.4%, and
27.6% vs 11.6%), and less commonly to Valve Heart Disease
(VHD) (10% vs 19.5% and 5.9% vs 14.4%).
Thus, HFmrEF again appears to stand somehow closer to
HFrEF (Table 1). Whether the two phenotypes share similarities
also for pathophysiology, is less clear. Large amount of data has
proven the paradigm of neurohormonal activation as a key concept
in the interpretation of progression of HFrEF, at the same time pro-
viding founding elements for a rational therapeutic strategy.
Currently, less is known about relative contribution of mild sys-
tolic impairment over diastolic dysfunction in HFmrEF. However,
conventional categories can still offer interesting insights into
problems, as proven by evaluation of temporal changes in EF and
transitions through different ranges. In 3480 patients with a median
follow-up of 3 years, Tsuji et al. [7] found that 21% with HFmrEF
transitioned to HFrEF and 45% to HFpEF; HFrEF transitioned in
21% of cases to HFmrEF and in 26% to HFpEF; conversely, only
8% of patients with HFpEF showed a downward transition.
Interestingly, IHD was the most relevant independent predictor of
EF worsening over time, for both HFmrEF and HFrEF: again, IHD
is therefore identified as the common load dragging HFmrEF
toward a worse prognosis. Of patients with HFmrEF from the
study by Rastogi et al. [10], 73% had previously had an EF <40%
and 17% an EF>50%; furthermore, Authors noted that among
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Table 1. Prevalence of different aetiologies across ranges of ejection fractions. 
Aetiology                                                            Reported prevalence (%)                                            Reference
                                                           HFpEF                    HFmrEF                     HFrEF
Ischemic heart disease                                     52.4                                   60.7                                     60                                        Vedin et al. [6]
                                                                                23.7                                   41.8                                   48.6                                       Chioncel et al. [9]
                                                                                44.1                                   52.9                                   50.1                                       Tsuji et al. [7] 
Valvular heart disease                                       14.4                                    5.9                                     4.4                                        Tsuji et al. [7]
                                                                                19.5                                     10                                      4.4                                        Chioncel et al. [9]
Hypertensive heart disease                             18.1                                    9.6                                     4.5                                        Chioncel et al. [9]
                                                                                24.5                                   14.3                                    9.3                                        Tsuji et al. [7]
Dilated cardiomyopathy                                     6.4                                    20.3                                   32.2                                       Tsuji et al. [7]
                                                                                11.6                                   27.6                                   35.1                                       Chioncel et al. [9]
HFpEF, heart failure with preserved ejection fraction; HFmrEF,: heart failure with mid-range ejection fraction; HFrEF, heart failure with reduced ejection fraction.
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patients with HFmrEF as a result of a deteriorating, previously
higher EF, diastolic dysfunction was more prevalent than among
those with improving EF. 
In both studies, an improving EF was associated with better
prognosis. Lupon et al. [11] recently reported a prospective, obser-
vational study of the dynamic trajectories of EF in 3160 patients
with HFrEF and HFmrEF over a 15-year follow-up. They found an
overall trend towards a marked rise in EF during the first year, with
a plateau up to a decade and a subsequent decline; such an inverted,
U-shaped curve was more evident in those with non-ischemic aeti-
ology and in women. Patients with HFmrEF had a less pronounced
EF increase (3±9%) than those with HFrEF (9±12%). Such observa-
tions suggest an intrinsic difference between HFrEF and HFpEF,
with HFmrEF being at the same time a transitional grey zone and a
category with inherent heterogeneity in pathophysiology. 
Therapeutic options
Trends in drug prescription among patients with HFmrEF in
current series [5,7] suggest either that this condition commonly
represents a recovered HFrEF with residual disease-specific ther-
apy or that clinicians believe that neurohormonal blockade may be
useful whenever a mild systolic impairment is present. Whether
such an approach is rational, is unclear. In the CHART-2 [7], beta-
blockers were found to reduce all-cause death in HFmrEF and
HFrEF (HR 0.57, p=0.010 and 0.59, p=0.008), respectively), but
not in HFpEF. Beneficial effect on 1-year all-cause mortality was
found also by Koh et al. [9], but within the narrower boundaries of
IHD for HFmrEF (HR 0.74, p=0.01 with IHD vs 0.99 without
IHD); surprisingly, a reverse benefit association was found for
HFpEF (HR 0.97, p=ns vs 0.81 without IHD). 
An individual patient-level meta-analysis on the efficacy of
beta-blockers [12] (including 575 patients with EF 40-49%) found a
reduction in mortality compared to placebo across all EF ranges in
sinus rhythm, except for those with EF >50%; cardiovascular mor-
tality was significantly reduced in HFmrEF (HR: 0.48, CI 95% =
0.24-0.97). Beta-blockers also increased EF at 1-year follow-up in
patients with baseline EF <50%, with smaller increase for HFmrEF
and for those of ischemic aetiology. Results from the CHARM [13]
trial across the whole EF spectrum, with limitations inherent to post-
hoc analysis, suggest a reduction in the primary composite end point
(cardiovascular death and HF hospitalization) in those treated with
the Angiotensin Receptor Blocker (ARB) candesartan, both in
patient with EF ≤40% and 40-49% (HR 0.82, p<0.001, and 0.76,
p=0.02, respectively), but not in patient with HFpEF. 
Of note, p for interaction was not significant, thus limiting
translational outlooks to hypothesis generation. In the TOPCAT
[14] trial, aimed at investigating the effects of spironolactone in
patients with symptomatic HF and EF ≥45%, this agent reduced
the combined end-point of cardiovascular death, HF hospitaliza-
tion or aborted cardiac arrest at the lower end of the explored EF
ranges (45-50%), but had no protective effect in patients with
EF≈60%.
Cardiac rehabilitation provides a multidisciplinary frame for
both educational and exercise training purposes in patients with
HFmrEF: not only it can address specific needs of the patients, as
exercise intolerance is a major complaint, but also allows active
counselling across steady and/or transitional phases. Inclusion in
rehabilitation programmes may thus be of high value in the contin-
uum of care.
We are still far from having clear therapeutic indications for
HFmrEF. Current ESC guidelines recommend screening patients for
comorbidities and prescribing diuretics to alleviate symptoms and
signs of heart failure [4]. Evidence suggests that therapeutic
response to available drugs in HFmrEF is closer to HFrEF, with aeti-
ology being a possible relevant issue in predicting such response.
Conclusions
HFmrEF was originated as a residual entity: there was not a
group of patients needing to be classified, but just a gap left unat-
tended between two different HF categories (HFrEF and HFpEF).
Much has been questioned about EF as a predictive measure.
However, current clinical practice suggests that, despite its many
conceptual and technical limitations, EF provides information that
are useful in HF management. Yet, it is clear what EF definitely
cannot do, i.e. identifying in itself a homogeneous group of
patients. HFmrEF is the case, since it is evident that an EF range
as narrow as absolute 10 percent is of limited utility in discriminat-
ing patients with a peculiar pathophysiology. Moreover, accuracy
in EF measurement may itself be a major limitation, since inter-
observer variability of echocardiography in untrained profession-
als may be wider than that range [15].
Overall, HFmrEF appears seems to be a transition category:
current observations have underscored that EF progression varies
with aetiology, time from onset and gender and that the path away
from - or back to - lower EF commonly passes through HFmrEF.
As such, a middle category may be useful just as long as it is the
occasion to make a question about past and future of a failing heart
- what brings a heart to recover or to further decline - with the aim
of helping clinicians understand the complexity that is hidden
behind a “border line” patient. 
References
1. Kishan SP, Kavita S, Mona F, et al.  Heart failure with pre-
served ejection fraction expert panel report. JACC Heart Fail
2018;6:619-32.
2. McMurray JJ, Adamopoulos S, Anker SD, et al.  ESC
Guidelines for the diagnosis and treatment of acute and chronic
heart failure 2012: The Task Force for the Diagnosis and
Treatment of Acute and Chronic Heart Failure 2012 of the
European Society of Cardiology. Developed in collaboration
with the Heart Failure Association (HFA) of the ESC. Eur J
Heart Fail 2012;14:803-69. 
3. Yancy CW, Jessup M, Bozkurt B, et al.  2013 ACCF/AHA
guideline for the management of heart failure: a report of the
American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines. J Am Coll
Cardiol 2013;62:e147-e239
4. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC
Guidelines for the diagnosis and treatment of acute and chronic
heart failure: The Task Force for the diagnosis and treatment of
acute and chronic heart failure of the European Society of
Cardiology (ESC). Developed with the special contribution of
the Heart Failure Association (HFA) of the ESC. Eur Heart J
2016;37:2129-200.
5. Koh AS, Tay WT, Teng TH, et al.A comprehensive population
based characterization of heart failure with mid-range ejection
fraction. Eur J Heart Fail 2017;19:1624-34. 
                          [Monaldi Archives for Chest Disease 2019; 89:1024]                                            [page 65]
                             Original Article
No
n-c
om
me
rci
l u
se
 on
ly
[page 66]                                             [Monaldi Archives for Chest Disease 2019; 89:1024]                          
6. Vedin O, Lam CS, Koh AS, et al. Significance of ischemic
heart disease in patients with heart failure and
preserved,midrange, and reduced ejection fraction: a nation-
wide cohort study. Circ Heart Fail 2017;10:e003875.
7. Tsuji K, Sakata Y, Nochioka K, et al. Characterization of heart
failure patients with mid-range left ventricular ejection frac-
tion - a report from the CHART-2 Study. Eur J Heart Fail
2017;19:1258-69
8. Bhambhani V, Kizer JR, Lima JA, et al. Predictors and out-
comes of heart failure with mid-range ejection fraction. Eur J
Heart Fail 2018;20:651-9. 
9. Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology
and one year outcomes in patients with chronic heart failure
and preserved, mid-range and reduced ejection fraction: an
analysis of the ESC Heart Failure Long-Term Registry. Eur J
Heart Fail 2017;19:1574-85. 
10. Rastogi A, Novak E, Platts AE, Mann DL. Epidemiology,
pathophysiology and clinical outcomes for heart failure
patients with a mid-range ejection fraction. Eur J Heart Fail
2017;19:1597-05. 
11. Lupón J, Gavidia-Bovadilla G, Ferrer E, et al. Trajectories of
left ventricular ejection fraction in heart failure. J Am Coll
Cardiol 2018;72:591-601.
12. Cleland JCF, Bunting KV, Flather MD, et al. Beta-blockers in
Heart Failure Collaborative Group; Beta-blockers for heart
failure with reduced, mid-range, and preserved ejection frac-
tion: an individual patient-level analysis of double-blind ran-
domized trials. Eur Heart  2018;39:26-35. 
13. Lund LH, Claggett B, LiuJ, et al. Heart failure with mid-range
ejection fraction in CHARM: characteristics, outcomes and
effect of candesartan across the entire ejection fraction spec-
trum. Eur J Heart Fail 2018;20:1230-39. 
14. Solomon SD, Claggett B, Lewis EF, et al. Influence of ejection
fraction on outcomes and efficacy of spironolactone in patients
with heart failure with preserved ejection fraction. Eur Heart J
2016;37:455-62.
15. McGowan JH, Cleland JG. Reliability of reporting left ventric-
ular systolic function by echocardiography: a systematic
review of 3 methods. Am Heart J 2003;146:388-97.
                             Original Article
No
n-c
om
me
rci
al 
us
e o
nly
